Distribution agreement for PromarkerD in Britain extended

We are pleased to announce the extension of our distribution agreement with medical diagnostics company Apacor Limited to bring the PromarkerD predictive test for diabetic kidney disease to patients in England, Scotland and Wales.

Since commencing work with Apacor several key milestones have been achieved in the UK, notably including PromarkerD being registered for use with the UK Medicines & Healthcare products Regulatory Agency, and the publication of National Institute for Health and Care Excellence (NICE) advice on PromarkerD.

In the United Kingdom an estimated 4.8 million people, or seven per cent of the population, live with type 2 diabetes. The UK’s National Health Service spends at least £10 billion per year on diabetes, equivalent to 10 per cent of its budget.

We are now working alongside Apacor towards the inclusion of PromarkerD in the NICE Guidelines and engaging with the NHS Supply Chain Tender process as part of the commercial roll-out of the test in the UK.

ASX Release